What is Ex Parte Baurin about?

PTAB rehearing on ODP rejection for antibody proteins; Board reversed examiner using Allergan precedent.

Does Allergan apply to non-family patents?

Professors say no — CAFC precedent like Fallaux allows later-filed references for ODP.

Will ARP change ODP rules for biotech?

Likely clarifies Allergan's limits, potentially backing examiners on expirations and ownership risks.

Professors Slam PTAB's ODP Pivot in High-Stakes Baurin Rehearing

A rare USPTO Appeals Review Panel dissects PTAB's bold ODP reversal. Professors Mark Lemley and Lisa Oullette fire back—CAFC history demands examiners' rejections stand.

theAIcatchup Apr 09, 2026 4 min read

USPTO Appeals Review Panel documents on Ex Parte Baurin ODP rehearing

⚡ Key Takeaways

Professors Lemley and Oullette cite CAFC precedent to back examiners' ODP rejections over PTAB's Allergan stretch. 𝕏
ARP probes Allergan's applicability, term projections, and ownership risks in Ex Parte Baurin. 𝕏
Baurin risks evergreening loopholes; ARP could realign PTAB with historical sustains. 𝕏

Published by

theAIcatchup

Where law meets technology.

#Allergan v MSN #CAFC precedent #Ex Parte Baurin #ODP #PTAB #PTAB decisions #obviousness double patenting

Worth sharing?

Get the best Legal Tech stories of the week in your inbox — no noise, no spam.

Originally reported by IPWatchdog

⚡ Key Takeaways

The 60-Second TL;DR

theAIcatchup

Share this article

Worth sharing?

Related Stories

85% of PTAB Patents Face Parallel Court Battles: Congress's AIA Tilted the Scales

Broad Institute Locks Down CRISPR Crown — Again — as PTAB Rejects UC's Last Shot

USPTO Crushes IPR Institutions by 43%: Patent Defenders Win Big

STRONGER Patents Act's Validity Loophole: Shield or Trap for Inventors?

Stay in the loop